Mounjaro®
Starting from £179.99/mo
Start journey Learn moreInsomnia is not listed as a recognised side effect of Mounjaro (tirzepatide) in its licensed prescribing information. Sleep disruption reported by some people on the treatment is more likely explained by gastrointestinal discomfort, nausea disturbing rest, or other indirect factors rather than a direct effect on sleep. That said, any new or persistent symptom during treatment deserves attention — and as a Prescription-Only Medicine, Mounjaro is prescribed only after a clinical assessment confirms it is suitable for you personally. Our prescribers discuss both expected and unexpected symptoms as part of that review.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A common assumption is that because Mounjaro slows digestion and alters appetite hormones, it must directly affect the brain's sleep regulation. It's an understandable leap, GLP-1 receptors do exist in the central nervous system. But the Mounjaro SmPC, which is the authoritative prescribing document published on the Electronic Medicines Compendium, does not list insomnia as an adverse reaction at any frequency. That doesn't mean no-one ever lies awake after a dose; it means the clinical evidence gathered across tens of thousands of participants in the SURMOUNT programme did not establish a causal link.
Let that assumption go gently. Sleep problems during weight-loss treatment are real, but the cause is usually indirect, and identifying the actual cause is what changes things for the better.
The NHS medicines page for tirzepatide lists the known side effects in plain language and is worth bookmarking for reference.
Nausea is one of the most commonly reported effects of tirzepatide, particularly in the early weeks and after each dose step. For some people it is mild and daytime-only; for others it lingers into the evening and makes comfortable rest difficult. Reflux and indigestion follow a similar pattern, stomach contents move more slowly on tirzepatide, which can mean lying flat at night worsens heartburn.
There is also the broader context of significant dietary change. Eating much less than usual, shifting meal timing, or inadvertently skimping on protein can all disturb normal sleep architecture. These are lifestyle-linked factors rather than pharmacological ones, which means they respond well to practical adjustments: a lighter evening meal, staying upright for a couple of hours after eating, and maintaining adequate protein intake during the day. If you want to understand more about how tirzepatide and insomnia are connected, including the indirect routes through which the medicine can affect rest, that page sets out the evidence clearly.
If you are curious how Mounjaro's gut-related effects compare across the range of things people report, our full Mounjaro side-effect overview covers the picture in more depth. For the specific question of what to make of an unexpected belching or reflux pattern at night, the burping and Mounjaro page addresses that directly.
Most gastrointestinal discomfort on tirzepatide is mild to moderate and time-limited. But some symptoms are a signal to act quickly rather than wait.
In January 2026, the MHRA issued a Drug Safety Update reminding clinicians and patients that acute pancreatitis is a known, infrequent but potentially serious effect of GLP-1 class medicines. The symptom to recognise is severe, persistent stomach pain that may spread toward the back, sometimes accompanied by vomiting, and which does not ease in the usual way. If that describes what you are experiencing, seek urgent medical attention rather than managing it at home.
Other reasons to contact a doctor promptly include signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing), significant dehydration from repeated vomiting or diarrhoea, and any mood changes or low thoughts that feel new or out of character. Sleep disturbance alone is unlikely to be one of these urgent scenarios, but if it is severe, unexplained and not improving, speaking to your prescriber sooner rather than later is sensible.
Suspected side effects (including any that feel unusual or unexpected) can be reported to the MHRA through the Yellow Card scheme. Reports from patients contribute to the ongoing safety monitoring of these medicines.
For a broader look at the less-discussed effects people notice on tirzepatide, including patterns like hair thinning and diarrhoea, the dedicated pages set out what the evidence does and does not show.
A question our prescribers hear regularly is whether a symptom someone is experiencing is from Mounjaro, from eating differently, or from something else entirely. The honest answer is often: it depends, and working that out is part of clinical review.
At nume, every consultation is read by a GPhC-registered Independent Prescriber, not processed by an automated system. Before Mounjaro is prescribed, they consider your full health picture (existing conditions, other medicines, lifestyle) and discuss what to realistically expect. If sleep disruption is something you have been experiencing, that conversation is the right place to raise it. Our aftercare team is also available seven days a week for exactly the kind of query that crops up between doses.
If you would like to understand the full range of what Mounjaro is and how it is used, the Mounjaro overview page is a good starting point. To explore whether private treatment might suit your situation, check your eligibility with a free consultation, there is no obligation, and our prescribers will be straightforward about what they can and cannot offer.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.